January 6, 2016
LivaNova: “FDA’s Warning Letter can be resolved without material impact on financial results”
LivaNova said that FDA’s Warning Letter can be resolved without a material impact on financial results.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
December 30, 2015
Midatech closes deal on acquiring Zuplenz
Midatech Pharma, the international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas, has…
December 14, 2015
AstraZeneca in talks to buy cancer drugmaker Acerta for $5 billion – WSJ
British drugmaker AstraZeneca Plc is in advanced talks to buy privately held cancer drug developer Acerta Pharma BV for more than $5 billion (£3.3 billion).
December 9, 2015
Bristol-Myers wraps up Cardioxyl buy. Dividend increase
Bristol-Myers Squibb Company has completed the previously announced planned acquisition of Cardioxyl Pharmaceuticals, Inc.
December 4, 2015
Genomic Vision partners up with the University-Hospital Institute (IHU) Imagine
Genomic Vision – has signed a strategic partnership with the University-Hospital Institute (IHU) Imagine, the largest European genetic research and care cluster.
December 4, 2015
MaSTherCell will fabricate TxCell’s ASTrIA platform products in Europe
TxCell SA has signed a 5-year agreement with MaSTherCell, a Contract Manufacturing Organization (CMO), based in Belgium.
According to this agreement, MaSTherCell will be the exclusive manufacturer in Europe of all products from TxCell’s ASTrIA platform.
December 1, 2015
Celyad advances first NKG2D CAR T-Cell Phase I study
Celyad advances first NKG2D CAR T-Cell Phase I study
December 1, 2015
French Biophytis appoints new Director of Research
Biophytis has appointed Pierre J. Dilda, PhD, as Director of
Research.
December 1, 2015
Frances Neovacs engaging in immuno-oncology
Neovacs, a France-based specialist in active immunotherapies for the treatment of autoimmune diseases, has decided to engage in the field of immuno-oncology after a recommendations by its Scientific Adivsory Board
December 1, 2015
Tuberculosis funding gap threatens elimination goals
Funding for tuberculosis research fell $1.3 billion short of global targets last year, threatening worldwide goals to eliminate the disease between 2030 and 2035, researchers said on Monday.